ArticlePDF Available

Primary Central Nervous System ALK Positive Anaplastic Large Cell Lymphoma with Predominantly Leptomeningeal Involvement in an Adult

Authors:

Abstract and Figures

A 31-year-old Korean male presented with altered consciousness and severe headache. Brain MRI delineated focal leptomeningeal enhancement without any intracerebral lesions. Diagnosis was made based on a brain biopsy showing anaplastic large cell lymphoma (ALCL), immunohistochemical stains revealing positivity for anaplastic lymphoma kinase (ALK) and an absence of involvement in any other organs; specifically, the primary central nervous system ALK+ALCL. Complete remission was achieved following 5 cycles of systemic chemotherapy with a high dose of Methotrexate and a simultaneous 7 cycles of intrathecal triple chemotherapy. Diagnosis of primary leptomeningeal ALK+ALCL is challenging given its rarity and non-specific symptoms along with non-pathognomonic radiologic findings. We present the first case of primary leptomeningeal ALK-positive ALCL where the clinical course, pathologic characteristics and treatment modality are described as well as a review of literature.
Content may be subject to copyright.
Yonsei Med J http://www.eymj.org Volume 54 Number 3 May 2013
791
Case Report http://dx.doi.org/10.3349/ymj.2013.54.3.791
pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 54(3):791-796, 2013
Primary Central Nervous System ALK Positive Anaplastic
Large Cell Lymphoma with Predominantly
Leptomeningeal Involvement in an Adult
Jae Sung Park,1,4* Heejung Park,5* Sanghui Park,5 Suk Jin Kim,3 Ho Jun Seol,1 and Young-Hyeh Ko2
Departments of 1Neurosurgery, 2Pathology, and 3Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul;
4Department of Neurosurgery, Konkuk University Chungju Hospital, Chungju;
5Department of Pathology, Ewha Womans University School of Medicine, Seoul, Korea.
Received: January 14, 2013
Revised: January 30, 2013
Accepted: January 30, 2013
Corresponding author: Dr. Young-Hyeh Ko,
Department of Pathology,
Samsung Medical Center,
Sungkyunkwan University School of Medicine,
50 Irwon-dong, Gangnam-gu,
Seoul 135-710, Korea.
Tel: 82-2-3410-2752, Fax: 82-2-3410-0025
E-mail: yhko310@skku.edu
*Jae Sung Park and Heejung Park contributed
equally to this work.
∙ The authors have no financial conflicts of
interest.
© Copyright:
Yonsei University College of Medicine 2013
This is an Open Access article distributed under the
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
A 31-year-old Korean male presented with altered consciousness and severe head-
ache. Brain MRI delineated focal leptomeningeal enhancement without any intrace-
rebral lesions. Diagnosis was made based on a brain biopsy showing anaplastic
large cell lymphoma (ALCL), immunohistochemical stains revealing positivity for
anaplastic lymphoma kinase (ALK) and an absence of involvement in any other or-
gans; specically, the primary central nervous system ALK+ALCL. Complete re-
mission was achieved following 5 cycles of systemic chemotherapy with a high
dose of Methotrexate and a simultaneous 7 cycles of intrathecal triple chemothera-
py. Diagnosis of primary leptomeningeal ALK+ALCL is challenging given its rari-
ty and non-specic symptoms along with non-pathognomonic radiologic ndings.
We present the rst case of primary leptomeningeal ALK-positive ALCL where the
clinical course, pathologic characteristics and treatment modality are described as
well as a review of literature.
Key Words: ALK-positive, primary, CNS, anaplastic large-cell lymphoma, lepto-
meningeal
INTRODUCTION
Anaplastic large cell lymphoma (ALCL), which had rst been described in 1985,
was acknowledged as a distinct clinicopathologic entity in 2001.1,2 The 4th edition
of the WHO Classication of Tumours of Haematopoietic and Lymphoid Tissues in
2008 states that anaplastic lymphoma kinase (ALK) positive ALCL [ALK(+)
ALCL] must be distinguished from the provisional entity of ALK-negative ALCL
[ALK(-)ALCL].3,4 Although ALCL is primarily a nodal disease, extranodal in-
volvement is not uncommon.5,6 Moreover, ALK(+)ALCL was reported to have a
higher frequency of extranodal involvement compared to ALK(-)ALCL; skin
(21%) was the most frequently involved organ followed by bone (17%) and soft tis-
sues (17%).7 Primary involvement in the central nervous system (CNS) of ALK(+)
ALCL, however, is exceptional and only eight cases of primary CNS ALCL with
Jae Sung Park, et al.
Yonsei Med J http://www.eymj.org Volume 54 Number 3 May 2013
792
CASE REPORT
A 31-year-old Korean male was brought to the emergency
department (ED) due to altered consciousness. At the ED,
he was drowsy and complained of a severe headache, weak-
ness in his left arm and difculty speaking. He stated that
he had been otherwise healthy and no laboratory results
suggested immunodeciency including human immunode-
ciency virus. Magnetic resonance imaging (MRI) of his
brain delineated leptomeningeal enhancement in the right
temporal and insular gyri (Fig. 1) and cerebrospinal uid
(CSF) analysis via lumbar puncture showed 90 WBC/mm3
with 67% of lymphocytes. Differential diagnosis at the time
included viral meningoencephalitis and tuberculosis (TB)
meningoencephalitis. Antiviral and anti-TB therapy were
started, neither of which was effective. His headache and al-
tered mental status were responsive only to Mannitol and
Dexamethasone. A follow-up MRI and CSF analysis, per-
formed 4 weeks after the initial visit to the ED, revealed
more prominent enhancement in the affected gyri and high-
er WBC counts (150/mm3) with elevated CSF pressure
(26.5 cm H2O), respectively. On the second CSF analysis
via lumbar puncture, a few scattered atypical lymphoid
cells were identied.
On the 39th hospital day, he underwent a brain biopsy fol-
lowing a craniotomy. The histologic section showed brain
parenchyma inltrated by numerous small-to-medium sized
neoplastic cells (Fig. 2A). These neoplastic cells had irregu-
lar nuclei with a moderate amount of cytoplasm (Fig. 2B).
Large atypical cells with horseshoe shaped nuclei, which
are hall mark cells of anaplastic large cell lymphoma, were
ALK positivity have been reported so far to our knowl-
edge.5,8-12 Although systemic ALK(+)ALCL tends to present
as an aggressive stage III or IV disease, it has been known to
be more responsive to chemotherapy than ALK(-)ALCL,
which contributes to better prognosis of the former than the
latter.2,5-7,13 Whereas the overall incidence of primary CNS
lymphoma was estimated to be 0.47 per 100,000 person-
years, only 14 cases of primary CNS ALCLs had been re-
ported by 2007: seven ALK(+)ALCLs, four ALK(-)ALCLs
and the remaining three ALCLs with ALK positivity untest-
ed.5,7,14 Seven (50%) of these 14 experienced a rapidly fatal
course leading to death and the mortality of primary CNS
ALCL was reported to be greater than that of other types of
CNS lymphomas in general.5,8,9,15-17 Treatment of choice for
primary CNS ALK(+)ALCL has not been established. In
this report, we describe the rst case of primary leptomenin-
geal ALK(+)ALCL of an adult man who was successfully
managed with systemic chemotherapy along with intrathe-
cal chemotherapy without radiotherapy.
Fig. 1. Magnetic resonance imaging of his brain showed hyperintense sig-
nal in the right temporal sulci from the Flair image (A) and leptomeningeal
enhancement in the right temporal and insular gyri from Gadolinium en-
hanced image (B).
Fig. 2. The histologic section showed brain parenchyma infiltrated by numerous small-to-medium sized neoplastic cells with perivascular cuffing of neoplas-
tic cells (A, HE ×100) and the neoplastic cells had irregular nuclei with a moderate amount of cytoplasm (B, HE ×400). Large atypical cells with horseshoe
shaped nuclei, which are hallmark cells of anaplastic large cell lymphoma, were also present (B, inset, HE ×1000)
A
A
B
B
Primary CNS Anaplastic Large Cell Lymphoma
Yonsei Med J http://www.eymj.org Volume 54 Number 3 May 2013
793
also present (Fig. 2B, inset). Immunohistochemical stains
revealed immunopositivity for CD30, ALK, Granzyme B,
CD45RO, CD5 and EMA (Fig. 3), but negative immunore-
activity for LCA, CD20, CD3, CD2, CD4, CD8, CD15,
CD43, CD68, BCL-2, CD56 and TIA-1. ALK was positive
in both the nucleus and cytoplasm. Fluorescence in situ hy-
bridization (FISH) was undertaken using a break apart
probe, which demonstrated translocations involving ALK
gene (Fig. 4). The case was diagnosed with malignant lym-
phoma of T-cell lineage, ALK+ALCL.
CT scans of his abdomen and chest failed to show any le-
sion suggesting involvement of lymphoma. A bone marrow
biopsy was performed, which was negative, and a test for
the Epstein-Barr virus was negative as well. On the seventh
post-biopsy day, he reported blindness in both eyes along
with severe headache, which indicated most likely very
high intracranial pressure (ICP). CSF pressure was mea-
sured to be over 40 cm H2O. Systemic high dose metho-
trexate (HD MTX, 8 g/mm2/day) and intrathecal (IT) triple
chemotherapy (MTX, Ara-C and Hydrocortisone) were im-
mediately started. After this, four more cycles of HD MTX
Fig. 3. Immunohistochemical stains revealed immunopositivity for CD30, ALK, Granzyme B, CD45RO and EMA. ALK, anaplastic lymphoma kinase.
Fig. 4. Fluorescence in situ hybridization for translocations involving ALK at
2p23: a unique sequence break apart probe targeting ALK gene locus was
used. Translocation involving ALK at 2p23 was detected. ALK, anaplastic
lymphoma kinase.
Jae Sung Park, et al.
Yonsei Med J http://www.eymj.org Volume 54 Number 3 May 2013
794
Primary CNS lymphomas with predominant involvement
of leptomeninges are harder to diagnose because both asep-
tic and septic meningoencephalitis should be ruled out rst.
Our patient was assumed to have viral or mycobacterial
meningoencephalitis given no gross mass seen upon brain
MRI. Primary leptomeningeal lymphomas account for only
about 7% of all adult primary CNS lymphomas.18 As seen
in Table 1, two of eight cases harbored predominantly lep-
tomeningeal involvement with no intracerebral lesions and
neither of them was an adult.11 Our case is the rst primary
leptomeningeal ALCL with ALK positivity in an adult. It
would inevitably take longer for patients with grossly sheer
leptomeningeal involvement to undergo a biopsy than those
who have one or more intracerebral lesions.
Among 8 reported cases, histologic subtypes were de-
scribed in only 4 cases. Three of these 4 cases showed com-
mon histologic subtypes and the remaining 1 was a com-
bined lymphohistiocytic and small cell variant. Our case
was common histologic subtype. All reported cases were
CD30 and ALK positive and have a T- or null cell pheno-
type, and most are EMA-positive. Our case was T-cell phe-
notype showing immunopositivity for CD45RO and CD5
but immunonegativity for CD3. As shown Figs. 3 and 4,
ALK was positive in both the nucleus and cytoplasm. ALK
gene translocation was also detected by FISH. These nd-
ings are consistent with the ALCL of NPM-ALK fusion
were repeated with the interval of three weeks. Seven cy-
cles of IT triple chemotherapy were simultaneously per-
formed in total with the interval of 4 days.
Other symptoms and problems that occurred during the
chemotherapy were generalized tonic clonic seizure, tremor
in his jaw with dystonic feature, hypotension, pneumonia,
central diabetes insipidus (DI) and minimal intracerebral
hemorrhage (ICH) in the right temporal lobe accompanied
with intraventricular hemorrhage (IVH). ICH and IVH did
not require a surgical decompression. A series of follow-up
MRI undertaken after the fth HD-MTX revealed no resid-
ual enhancement, which suggested complete remission
(CR). Although mild quadriparesis and jaw dystonia re-
mained, no evidence of recurrence has been noted for more
than six months since CR.
DISCUSSION
Diagnosis of primary CNS ALK+ALCL requires several
critical steps including: clinical suspicion even when no
gross mass exists, biopsy in a timely manner, a thorough
immunohistochemical study, and exclusion of metastasis.
Given that extranodal involvement of ALK(+)ALCL is rel-
atively common, diagnosis of primary CNS ALK(+)ALCL
must be made only after excluding other involvement.5,6
Table 1. Summary of All Documented Cases of Primary CNS ALK+ALCL
Sex/Age Symptoms Location Clinical suspicion Histologic
subtype Clinical outcome
Abdulkader, et al.8M/13 Headache, vomiting Pariental and frontal lobe Infection Common Death
Ponzoni, et al.10 M/29 Fever, headache,
seizure Frontal and temporal lobe Infection/tumor
Lympho-
histiocytic
and small cell
NED at 13 mo
George, et al.9M/17 NA Parietal dura NA NA NED at 4.8 yrs
George, et al.9F/18 NA Temporal lobe and dura NA NA NED at 5.2 yrs
Karikari, et al.5M/4 Seizure
Pineal region mass,
leptomeningeal
enhancement
Infection Common Alive, ED
Merlin, et al.11 M/13 Headache, nausea Leptomeningeal
enhancement NA NA Death
Ozkaynak12 M/9 Seizure Frontal lobe Infection/abscess NA NED at 26 mo
Shah, et al.21 M/23
mo
Lethargy, motor
function loss,
seizure
Rt hemispheric and
leptomenigeal
enhancing mass
Tumor Common NED at 8 yrs
The present case M/31 Headache, seizure
Rthemispheargyral
swelling, leptomeningeal
enhancement
Infection Common NED at 18 mo
M, male; F, female; Mo, month; yr, year; NA, not available; Rt, right; NED, no evidence of disease; ED, evidence of disease; CNS, central nervous system;
ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma.
Primary CNS Anaplastic Large Cell Lymphoma
Yonsei Med J http://www.eymj.org Volume 54 Number 3 May 2013
795
creased ICP with meningeal irritation, CSF analysis reveal-
ing atypical lymphoid cells, no gross mass detected in the
brain MRI and lack of symptomatic improvement by anti-
viral, antibiotic or anti-TB medications.
REFERENCES
1. Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen
G, et al. The expression of the Hodgkin’s disease associated anti-
gen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that
Reed-Sternberg cells and histiocytic malignancies are derived
from activated lymphoid cells. Blood 1985;66:848-58.
2. Jaffe ES, Harris NL, Stein H, Wardiman JW. Tumors of haemato-
poietic and lymphoid tissues. Lyon: IARC Press; 2001.
3. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES.
The 2008 WHO classication of lymphoid neoplasms and beyond:
evolving concepts and practical applications. Blood 2011;117:
5019-32.
4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H,
et al. WHO Classification of Tumours of Haematopoietic and
Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
5. Karikari IO, Thomas KK, Lagoo A, Cummings TJ, George TM.
Primary cerebral ALK-1-positive anaplastic large cell lymphoma
in a child. Case report and literature review. Pediatr Neurosurg
2007;43:516-21.
6. Penny RJ, Blaustein JC, Longtine JA, Pinkus GS. Ki-1-positive
large cell lymphomas, a heterogenous group of neoplasms. Mor-
phologic, immunophenotypic, genotypic, and clinical features of
24 cases. Cancer 1991;68:362-73.
7. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-
Peeters C, et al. ALK+ lymphoma: clinico-pathological ndings
and outcome. Blood 1999;93:2697-706.
8. Abdulkader I, Cameselle-Teijeiro J, Fraga M, Rodriguez-Núnez A,
Allut AG, Forteza J. Primary anaplastic large cell lymphoma of
the central nervous system. Hum Pathol 1999;30:978-81.
9. George DH, Scheithauer BW, Aker FV, Kurtin PJ, Burger PC,
Cameselle-Teijeiro J, et al. Primary anaplastic large cell lympho-
ma of the central nervous system: prognostic effect of ALK-1 ex-
pression. Am J Surg Pathol 2003;27:487-93.
10. Ponzoni M, Terreni MR, Ciceri F, Ferreri AJ, Gerevini S, Anza-
lone N, et al. Primary brain CD30+ ALK1+ anaplastic large cell
lymphoma (‘ALKoma’): the rst case with a combination of ‘not
common’ variants. Ann Oncol 2002;13:1827-32.
11. Merlin E, Chabrier S, Verkarre V, Cramer E, Delabesse E, Stéphan
JL. Primary leptomeningeal ALK+ lymphoma in a 13-year-old
child. J Pediatr Hematol Oncol 2008;30:963-7.
12. Ozkaynak MF. Favorable outcome of primary CNS anaplastic
large cell lymphoma in an immunocompetent patient. J Pediatr
Hematol Oncol 2009;31:128-30.
13. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T,
Takeshita M, et al. Anaplastic large cell lymphomas expressing
the novel chimeric protein p80NPM/ALK: a distinct clinicopatho-
logic entity. Blood 1995;86:1954-60.
14. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age,
gender, and racial differences in incidence and survival in primary
CNS lymphoma. Br J Cancer 2011;105:1414-8.
15. Buxton N, Punt J, Hewitt M. Primary Ki-1-positive T-cell lym-
gene, as a consequence of the t(2;5)(2p23;5q35). The ma-
jority (60-80%) of ALK(+)ALCL display a characteristic
chromosomal translocation involving the NPM gene locat-
ed at 5q35 with the ALK gene on 2p23.4
Treatment of choice for primary CNS ALK(+)ALCL has
not been established mainly due to its great rarity. For pedi-
atric patients, combined systemic chemotherapy and CNS
radiation is usually administered, although a recent report
suggested that combination of systemic and intrathecal che-
motherapy without cranial radiotherapy should be safer and
more efcient.19,20 The risk of whole-brain irradiation lead-
ing to long-term complications is known to be substantial
in children; therefore, sooner consensus on the most effec-
tive chemotherapeutic regimen should be reached in order
to avoid or at least delay radiotherapy.21 Our patient achieved
CR following 5 cycles of HD MTX along with 7 cycles of
IT triple chemotherapy without craniospinal radiotherapy.
He suffered from several temporary problems such as se-
vere headache, blindness, seizure and central DI. Long-term
complications included quadriparesis and dystonia in the
jaw. Some of these temporary and permanent complications
were assumed to derive from severely elevated intracranial
pressure, rather than from lymphoma itself. Therefore, these
complications may have been avoided if the chemotherapy
had been started sooner enough. As mentioned earlier,
grossly sheer leptomeningeal involvement without an intra-
cranial lesion contributed to belated brain biopsy leading to
delayed commencement of chemotherapy. According to a
report in 2007, seven of 14 patients with primary CNS
ALCL died; two of them had ALK(+)ALCL, three had
ALK(-)ALCL and the remaining two did not go through the
test for ALK positivity.5 Given the insufcient sample size
to be statistically significant, prognosis of primary CNS
ALK(+)ALCL compared to ALK(-)ALCL is inconclu-
sive.5,9,11 In addition, there are no statistically signicant data
on prognosis of primary CNS ALCL compared to CNS lym-
phomas in general, but the mortality of the former seemed to
be greater than that of the latter.5,17 Systemic ALK(+)ALCL
has been known to be more responsive to chemotherapy
leading to better prognosis than ALK(-)ALCL, but this does
not seem to apply to primary CNS ALCLs.5
In conclusion, this is the first reported case of primary
leptomeningeal ALK(+)ALCL in an adult to our knowl-
edge. Early detection is of vital importance in terms of both
mortality and morbidity. Physicians should consider the
possibility of leptomeningeal lymphomas in a patient with
symptoms mimicking those of meningitis including in-
Jae Sung Park, et al.
Yonsei Med J http://www.eymj.org Volume 54 Number 3 May 2013
796
19. Taga T, Sakaue Y, Anzai Y, Takeuchi Y, Ohta S. Pediatric primary
leptomeningeal lymphoma treated without cranial radiotherapy.
Pediatr Blood Cancer 2007;48:477-8.
20. Felice MS, Zubizarreta PA, Rossi JG, Rose A, Alfaro EM, Sack-
mann-Muriel F. Diagnosis and successful treatment of childhood
primary leptomeningeal lymphoma. Med Pediatr Oncol 2000;34:
361-3.
21. Shah AC, Kelly DR, Nabors LB, Oakes WJ, Hilliard LM, Reddy
AT. Treatment of primary CNS lymphoma with high-dose metho-
trexate in immunocompetent pediatric patients. Pediatr Blood
Cancer 2010;55:1227-30.
phoma of the brain in a child. Pediatr Neurosurg 1998;29:250-2.
16. Goldbrunner R, Warmuth-Metz M, Tonn JC, Vince GH, Roosen
K. Primary Ki-1-positive T-cell lymphoma of the brain--an ag-
gressive subtype of lymphoma: case report and review of the liter-
ature. Surg Neurol 1996;46:37-41.
17. Paulus W, Ott MM, Strik H, Keil V, Müller-Hermelink HK. Large
cell anaplastic (KI-1) brain lymphoma of T-cell genotype. Hum
Pathol 1994;25:1253-6.
18. Lachance DH, O’Neill BP, Macdonald DR, Jaeckle KA, Witzig
TE, Li CY, et al. Primary leptomeningeal lymphoma: report of 9
cases, diagnosis with immunocytochemical analysis, and review
of the literature. Neurology 1991;41:95-100.
... Primary CNS anaplastic large cell lymphomas (ALCLs) are rare, most of which are ALK+, while only a minority of cases are ALK-1 negative(3). Up to date, only few cases of primary CNS ALK + ALCL have been reported, mainly as case reports rather than as study series (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Because of its rarity, the clinicopathologic and prognostic features of primary CNS ALK + ALCL have not been well illuminated. ...
... After an extensive search of the English literature, we found 20 cases of primary CNS ALK+ ALCL (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Some cases were included in two articles with different study purposes, and the data from these cases were carefully extracted and combined. ...
Preprint
Full-text available
Background Primary CNS anaplastic lymphoma kinase-positive (ALK+) anaplastic large cell lymphoma (ALCL) is extremely rare and only few cases have been reported. Due to its rarity, the clinicopathologic features and the prognosis of primary CNS ALK + ALCL have not been well characterized. Methods We retrospectively analyzed the clinicopathologic and prognostic features of 3 cases of primary CNS ALK + ALCLs among 337 cases of primary CNS lymphomas during the past 14 years in our cancer center with review of an additional 20 cases from the literature. Results Primary CNS ALK + ALCL accounted for 0.9% (3/337) of all primary CNS lymphomas during the study period in our cancer center. The ages of patients ranged from 4 to 43 years, with a median age of 18 years. There was a predominance of males, with the male-to-female ratio of 6.7:1. Most (87%, 20/23) of cases had intracerebral mass(es), and among these cases, 25% (5/20) of cases were accompanied by involvement of spinal cord and (or) leptomeninges; rare cases (3/23,13%) were confined to the spinal cord and (or) leptomeninges. A solitary mass and multiple tumors were present in 56.5% (13/23) and 43.5% (10/23) of cases, respectively. Of the 22 patients with survival data, 31.8% (7/22) of patients died of the disease during the follow-up period (median follow-up, 24 months; range, 0.5–87 months). The 2-year overall survival (OS) of patients with primary CNS ALK + ALCL was 69%. Patients under 18-years old had worse 2-year overall survival, but the difference did not reach statistical significance (p = 0.115). No statistical significance was found between patients with solitary mass and multiple tumors (p = 0.940). Conclusions Primary CNS ALK + ALCL is an extremely rare disease and tends to occur in young adults with a male preponderance. Patients with this disease have relatively favorable outcome than other types of primary CNS lymphomas. Accurate diagnosis, as well as timely and optimal treatment for patients with this disease is important.
... ALK FISH was reported in only six cases, and an NPM1-ALK gene rearrangement was only reported twice. There were several cases with cytoplasmic ALK Positive Negative Not reported Havlioglu et al 3 Buxton et al 4 Abdulkader et al 5 Ponzoni et al 6 George et al 7 (1) George et al 7 (2) Rupani et al 8 Cooper et al 9 Karikari et al 10 Carmichael 11 Merlin et al 12 Ozkaynak 13 Shah et al 14 Vivekanandan et al 15 Nomura et al 16 Park et al 17 Kim et al 18 Geetha et al 19 Kim et al 20 Furuya et al 21 Menon et al 22 Dunbar et al 23 Kuntegowdenahalli et al 24 Splvaski et al 25 Dong et al 26 Kaku et al 27 Feng et al 28 Hirano et al 29 Lee et al 30 Liu et al 31 Strosberg and Sagatys et al 32 Case 1 Case 2 Case 3 CD45 CD30 ALK EMA CD3 CD2 CD4 CD5 CD7 CD8 CD43 CD20 Granzyme B TIA-1 FIGURE 3 Immunohistochemical profile of primary central nervous system anaplastic large cell lymphoma, anaplastic lymphoma kinase positive. The immunohistochemical staining profile for prior reported cases and the current cases is summarized. ...
Article
Objectives: Primary central nervous system anaplastic large cell lymphoma, anaplastic lymphoma kinase positive (primary CNS ALCL, ALK+) is a rare CNS lymphoma whose description is limited to case reports. These tumors have a variable clinical course, and prognosis is primarily determined by age. We present the largest case series to date of primary CNS ALCL, ALK+, with observational data. Methods: A retrospective search of multiple academic centers was performed to identify cases of primary CNS ALCL, ALK+. We also performed a review of published cases of primary CNS ALCL, ALK+. Clinical history, radiography, pathology, and genetic testing data were obtained to determine the prognostic implications in the context of clinical course. Results: We identified three cases of primary CNS ALCL, ALK+ from our databases. A literature review identified 30 published reports of 31 individual cases. Clinical features for the combined 34 cases included a median age of 18.5 years, with a male to female ratio of 4.7:1, and the most common symptom was headache. Genetic studies demonstrated an ALK rearrangement by fluorescence in situ hybridization, and a gene fusion assay confirmed an NPM1-ALK gene fusion in one case. Conclusions: We present the largest case series to date of a rare primary CNS lymphoma with additional diagnostic and clinical information.
... Many cases have previously been classified as PTCL, NOS, with tumor cells often showing small-to-medium sized nuclei of low-grade appearance. Although the cases are few in number, both ALK-positive and ALK-negative, primary CNS ALCL have been reported (8,9). The lymphoma cells show large nuclei of severe atypia, suggesting the presence of aggressive features. ...
... Involvement of the leptomeninges in ALCL is a common feature. Of the 24 cases of primary CNS ALCL that have been described 21,25,[43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61] , 10 cases demonstrated some degree of dural or leptomeningeal involvement. In addition, there are 2 documented cases of primary dural ALCL without CNS parenchymal involvement 44,45 . ...
Article
Primary central nervous system (CNS) lymphomas are relatively rare with the most common subtype being diffuse large B-cell lymphoma. Primary CNS T-cell lymphomas (PCNSTL) account for <5% of CNS lymphomas. We report the clinical, morphologic, immunophenotypic, and molecular characteristics of 18 PCNSTLs. Fifteen cases were classified as peripheral T-cell lymphoma, not otherwise specified, 2 of which were of γδ T-cell derivation and 1 was TCR silent; there was 1 anaplastic large cell lymphoma, ALK-positive and 2 anaplastic large cell lymphoma, ALK-negative. Median age was 58.5 years (range, 21 to 81 y), with an M:F ratio of 11:7. Imaging results showed that 15 patients had supratentorial lesions. Regardless of subtype, necrosis and perivascular cuffing of tumor cells were frequently observed (11/18 cases). CD3 was positive in all cases but 1; 10/17 were CD8-positive, and 5/17 were CD4-positive. Most cases studied had a cytotoxic phenotype with expression of TIA1 (13/15) and granzyme-B (9/13). Polymerase chain reaction analysis of T-cell receptor γ rearrangement confirmed a T-cell clone in 14 cases with adequate DNA quality. Next-generation sequencing showed somatic mutations in 36% of cases studied; 2 had >1 mutation, and none showed overlapping mutations. These included mutations in DNMT3A, KRAS, JAK3, STAT3, STAT5B, GNB1, and TET2 genes, genes implicated previously in other T-cell neoplasms. The outcome was heterogenous; 2 patients are alive without disease, 4 are alive with disease, and 6 died of disease. In conclusion, PCNSTLs are histologically and genomically heterogenous with frequent phenotypic aberrancy and a cytotoxic phenotype in most cases.
Article
Full-text available
Primary central nervous system (CNS) ALK-negative anaplastic large cell lymphoma (ALCL) is a rare and enigmatic disease, with limited data available in the literature. This case report adds to the existing body of knowledge by describing a unique case of a 68-year-old, immunocompetent male who presented with a single ring-enhancing lesion, which upon further analysis proved to be an ALK-negative ALCL that was primary to the CNS. A comprehensive review of the existing literature is provided, highlighting the genetic characteristics and diverse neuroimaging findings of this disease entity. This report adds valuable information to the understanding of this rare disorder, and highlights the need for further research in the field of primary CNS ALK-negative ALCL.
Article
Full-text available
Primary anaplastic large cell lymphoma (ALCL) of the central nervous system (CNS) is a subtype of primary CNS lymphoma (PCNSL). There are very few comprehensive reports on this extremely rare tumor. Therefore, it is necessary to investigate the clinical features and prognostic factors for primary ALCL of the CNS. We performed a systematic review of the published literature. Past cases were comprehensively searched using PubMed, Cochrane Library, and Web of Science. Clinical information, such as age, sex, anaplastic lymphoma kinase (ALK) status, lesion sites, treatment methods, and survivorship were extracted. Thirty-nine cases with information on ALK status and treatment course were identified. The average observation period was 13 months, and the overall 2-year survival rate was 58%. Univariate analyses showed a statistically significantly better prognosis among patients < 40 years of age (p = 0.039, HR 0.32 (0.11–0.95)) and in relation to ALK positivity (p = 0.010, HR 0.24 (0.08–0.71) and methotrexate treatment (p = 0.003, HR 0.17 (0.05–0.56)). Because of the sparsity of cases, it is necessary to accumulate cases in order to perform more detailed analyses.
Article
Background Central nervous system (CNS) lymphomas frequently pose a diagnostic challenge to physicians. CNS anaplastic large cell lymphoma (ALCL) is a rare condition. A majority (80%) of ALCLs harbour anaplastic lymphoma kinase 1 (ALK-1) mutation with only a minority testing negative for this mutation. Methods Here we report a rare case of ALK-negative CNS ALCL with dural involvement. We conducted a literature search using PubMed for published studies in English on cases of patients with ALCL of the brain. The keywords used were ‘anaplastic large cell lymphoma’, ‘ALK’ and ‘primary central nervous system lymphoma’. Results A 63-year-old man presents with waxing and waning cranial nerve and spinal cord symptoms. MRI revealed multiple intracranial and intra-spinal lesions that were highly steroid responsive. A wide range of serum and CSF tests were non-diagnostic during three months of workup before a lesion appeared in the cervical spine that required decompression and allowed us to obtain a tissue sample. Final pathology revealed ALK-negative ALCL. There are only 24 reported adult cases to date of CNS ALCL in the English literature. To our knowledge, this is the first case of ALK-negative ALCL with primarily CNS and meningeal involvement. Conclusions ALK-negative ALCL with CNS involvement is extremely rare, which frequently results in delayed diagnosis (average 40.5 days). The diagnostic challenge posed by this case highlights the importance of a team approach to workup and diligent patient follow-up for such a rare disease.
Article
Primary lymphoid neoplasms of the central nervous system are rare tumors that span a wide range of histopathologic appearances and can overlap occasionally with non-neoplastic processes. Application of modern molecular techniques has not only begun to unravel their unique underlying biology but has also started to lay a valuable diagnostic and therapeutic framework for these frequently aggressive malignancies. This review summarizes the existing landscape of clinicopathologic and genomic features of lymphoid neoplasms that may arise primarily within the central nervous system.
Article
CSF involvement in cases of systemic ALCL is rarely reported. However CSF study should be done in all cases of NHL when the patient is symptomatic, although the radiology may be normal.
Article
There have been 23 reports of primary central nervous system anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma in the literature. Here we report the 24th case of a 40-year-old man who presented with occipital headache for one month. His contrast-enhanced brain MRI showed enhancement around the right temporal lobe, which suggested a diagnosis of hypertrophic pachymeningitis. He improved with steroid therapy. After discharge, however, he was readmitted with generalized convulsive seizures. Finally, he was diagnosed as primary central nervous system ALK-positive anaplastic large cell lymphoma by brain biopsy. Primary central nervous system lymphoma invading dura matter can rarely manifests as a unilateral pachymeningitis. Therefore, in case of pachymeningitis, we should pay attention to the possibility of infiltration of lymophoma with meticulous clinical follow-up.
Article
Full-text available
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma that accounts for ~4% of newly diagnosed central nervous system (CNS) tumours. The objective of this study was to analyse the epidemiology, incidence, and outcome of these rare tumours. Primary brain and CNS lymphoma cases were identified from the Surveillance, Epidemiology, and End Results (SEER) research data sets for the years 1980-2008 for analysis of trends in incidence and survival. SEER(*)Stat v. 7.0.4 software was used to analyse the data. The overall incidence rate of PCNSL was 0.47 per 100,000 person-years. The incidence was significantly higher in males compared with females, blacks aged 0-49 years at diagnosis compared with whites, and whites aged 50 years and older at diagnosis compared with blacks. After a significant decline in incidence between 1995 and 1999, incidence rates rose slightly; those aged 75+ years at diagnosis had the most dramatic increase in incidence rates over time. Five-year survival rates were significantly higher in whites compared with blacks aged 0-49 years at diagnosis, but was primarily driven by white women aged 0-49 years. There is an increase in incidence of PCNSL in the elderly, and elderly blacks have lower incidence compared with white population. Survival remains poor and is negatively dominated by factors associated with HIV infection and advanced age.
Article
Full-text available
The World Health Organization classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors and is based on the recognition of distinct diseases, using a multidisciplinary approach. The updated classification refined the definitions of well-recognized diseases, identified new entities and variants, and incorporated emerging concepts in the understanding of lymphoid neoplasms. However, some questions were unresolved, such as the extent to which specific genetic or molecular alterations define certain tumors, and the status of provisional entities, categories for which the World Health Organization working groups felt there was insufficient evidence to recognize as distinct diseases at this time. In addition, since its publication, new findings and ideas have been generated. This review summarizes the scientific rationale for the classification, emphasizing changes that have had an effect on practice guidelines. The authors address the criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly. The issue of borderline categories having overlapping features with large B-cell lymphomas, as well as several provisional entities, is reviewed. These new observations chart a course for future research in the field.
Article
Full-text available
The Histiocytoses are defined as non-malignant disorders due to abnormal accumulation and behavior of cells of the mononuclear phagocytic system. The best known histiocytoses, Langerhans cell histiocytosis (LCH), and hemophagocytic lymphohistiocytosis (HLH), each with an estimated incidence of 1/50,000 to 1/150,000, are sufficiently "common," complex and costly, to constitute an important problem in medical practice. At the same time, LCH, HLH and an array of other and more rare histiocytoses are sufficiently uncommon that most physicians lack the experience to diagnose, let alone care for patients with these conditions. The pathophysiology of most of the histiocytoses is unknown and, in the case of the widely-disseminated and potentially fatal forms, treatments to date have been variably effective and sometimes highly toxic. MAS has been reported to occur in association with almost any rheumatic disease, it is by far most common in the systemic form of Juvenile Idiopthic Arthritis (SoJIA). It is now recognized that MAS bears a close resemblance to Hemophagocytic Lymphohistiocytosis or HLH, and MAS is recognized as the major fatal complication of soJIA.
Article
Ki-1 is a monoclonal antibody (raised against a Hodgkin's disease- derived cell line) that, in biopsy tissue affected by Hodgkin's disease, reacts selectively with Reed-Sternberg cells. The expression of Ki-1 antigen has been analyzed by immunocytochemical techniques in a wide range of human tissue and cell samples, including fetal tissue, malignant lymphomas (290 cases), and mitogen- and virus-transformed peripheral blood lymphocytes. The antigen was detectable on a variable proportion of cells in all cases of lymphomatoid papulosis and angio- immunoblastic lymphadenopathy and in 28% of the cases of peripheral T cell lymphomas (including lympho-epithelioid lymphomas). It was also expressed (more strongly) on tumor cells in 45 cases of diffuse large- cell lymphoma, most of which had originally been diagnosed as malignant histiocytosis or anaplastic carcinoma, because of their bizarre morphology. However, all of these cases lacked macrophage and epithelial antigens. Thirty-five cases expressed T cell-related antigens (associated in nine cases with the coexpression of B cell- related antigens), seven bore B cell-related antigens alone, and three were devoid of T and B cell markers. DNA hybridization with a JH specific probe showed a germline configuration in 11 cases of T cell phenotype, in two cases lacking T and B cell antigens, and in one case of mixed T/B phenotype, while rearrangement was found in two cases of clear B cell type and in one mixed T/B case. Expression of the Ki-1 antigen could be induced, together with interleukin 2 (IL 2) receptor, on normal lymphoid cells of both T and B cell type by exposure to phytohemagglutinin, human T leukemia viruses, Epstein-Barr virus, or Staphylococcus aureus. The results obtained indicate that Ki-1 antigen is an inducible lymphoid-associated molecule that identifies a group of hitherto poorly characterized normal and neoplastic large lymphoid cells. Tumors comprised solely of these cells show both morphological and immunological similarities to the neoplastic cells in Hodgkin's disease. This suggests that both disorders represent the neoplastic proliferation of activated lymphoid cells of either T cell or, less commonly, B cell origin. Disorders in which only a minority of cells express Ki-1 antigen (lymphomatoid papulosis, angio-immunoblastic lymphadenopathy, and certain T cell lymphomas) probably represent lesions in which only some of the abnormal cells have transformed into an “activation state.” In direct support of this view is the finding that the Ki-1 expression in these lesions is accompanied by the expression of HLA-DR and IL 2 receptors.
Article
Ki-1 is a monoclonal antibody (raised against a Hodgkin's disease- derived cell line) that, in biopsy tissue affected by Hodgkin's disease, reacts selectively with Reed-Sternberg cells. The expression of Ki-1 antigen has been analyzed by immunocytochemical techniques in a wide range of human tissue and cell samples, including fetal tissue, malignant lymphomas (290 cases), and mitogen- and virus-transformed peripheral blood lymphocytes. The antigen was detectable on a variable proportion of cells in all cases of lymphomatoid papulosis and angio- immunoblastic lymphadenopathy and in 28% of the cases of peripheral T cell lymphomas (including lympho-epithelioid lymphomas). It was also expressed (more strongly) on tumor cells in 45 cases of diffuse large- cell lymphoma, most of which had originally been diagnosed as malignant histiocytosis or anaplastic carcinoma, because of their bizarre morphology. However, all of these cases lacked macrophage and epithelial antigens. Thirty-five cases expressed T cell-related antigens (associated in nine cases with the coexpression of B cell- related antigens), seven bore B cell-related antigens alone, and three were devoid of T and B cell markers. DNA hybridization with a JH specific probe showed a germline configuration in 11 cases of T cell phenotype, in two cases lacking T and B cell antigens, and in one case of mixed T/B phenotype, while rearrangement was found in two cases of clear B cell type and in one mixed T/B case. Expression of the Ki-1 antigen could be induced, together with interleukin 2 (IL 2) receptor, on normal lymphoid cells of both T and B cell type by exposure to phytohemagglutinin, human T leukemia viruses, Epstein-Barr virus, or Staphylococcus aureus. The results obtained indicate that Ki-1 antigen is an inducible lymphoid-associated molecule that identifies a group of hitherto poorly characterized normal and neoplastic large lymphoid cells. Tumors comprised solely of these cells show both morphological and immunological similarities to the neoplastic cells in Hodgkin's disease. This suggests that both disorders represent the neoplastic proliferation of activated lymphoid cells of either T cell or, less commonly, B cell origin. Disorders in which only a minority of cells express Ki-1 antigen (lymphomatoid papulosis, angio-immunoblastic lymphadenopathy, and certain T cell lymphomas) probably represent lesions in which only some of the abnormal cells have transformed into an “activation state.” In direct support of this view is the finding that the Ki-1 expression in these lesions is accompanied by the expression of HLA-DR and IL 2 receptors.
Article
We report two cases of primary CNS lymphoma (PCNSL) treated with high-dose methotrexate. Though standard adult treatment of PCNSL incorporates whole-brain radiotherapy, the literature suggests it may be possible to delay or avoid radiotherapy and the associated increased risk of neurologic sequelae in pediatric patients. Studies in adults indicate methotrexate therapy can be effective against PCNSL and has advantages over the current standard of treatment. Both patients have no evidence of disease 9 and 7 years after treatment, suggesting high-dose methotrexate may lead to disease control in pediatric patients with PCNSL while avoiding the effects of radiotherapy.